Nalaganje...

Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist (rhIL1RA) for Sepsis Varies by Initial IL1RA Plasma Concentration

OBJECTIVE: Plasma interleukin-1 beta (IL1β) may influence sepsis mortality, yet recombinant human interleukin-1 receptor antagonist (rhIL1RA) did not reduce mortality in randomized trials. We tested for heterogeneity in the treatment effect of rhIL1RA by baseline plasma IL1β or IL1RA concentration....

Popoln opis

Shranjeno v:

Bibliografske podrobnosti
izdano v:	Crit Care Med
Main Authors:	Meyer, Nuala J., Reilly, John P., Anderson, Brian J., Palakshappa, Jessica A., Jones, Tiffanie K., Dunn, Thomas G., Shashaty, Michael G.S., Feng, Rui, Christie, Jason D., Opal, Steven M.
Format:	Artigo
Jezik:	Inglês
Izdano:	2018
Teme:	Article
Online dostop:	https://ncbi.nlm.nih.gov/pmc/articles/PMC5734955/ https://ncbi.nlm.nih.gov/pubmed/28991823 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCM.0000000000002749
Oznake:	Označite Brez oznak, prvi označite!

Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist (rhIL1RA) for Sepsis Varies by Initial IL1RA Plasma Concentration

Podobne knjige/članki